ReviewOxidative medicine and cellular longevity2016
Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis.
Review in Oxidative medicine and cellular longevity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Role of galectin-3 as a biomarker in obstructive sleep apnea: a systematic review and meta-analysis.Sleep & breathing = Schlaf & Atmung · 2023Pooled it
- Serum Galectin-3 in Diabetic Foot Infections: A Case-Control Evaluation of Its Diagnostic and Severity-Grading Utility.Infectious diseases & clinical microbiology · 2026Article
- Elevated serum galectin-3 levels predict the incidence of type 2 diabetes mellitus in a Japanese general population: A 10-year follow-up study.Journal of diabetes investigation · 2026Article
- PerturbingCells · 2026Article
- Article
- Galectin-3 inhibitor selvigaltin dosed therapeuticallyFrontiers in physiology · 2026Article
- Pleiotropic regulatory mechanisms and targeted therapeutic prospects of Galectin-3 in aging-related diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- The Dual Role of Perivascular Adipose Tissue in Vascular Homeostasis and Atherogenesis: From Physiology to Pathological Implications.International journal of molecular sciences · 2025Review
- Galectin-3-Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- New Markers for the Assessment of Microvascular Complications in Patients with Metabolic Syndrome.Metabolites · 2025Review
- Galectins and Liver Diseases.International journal of molecular sciences · 2025Review
- Predictive Value of NT-proBNP, FGF21, Galectin-3 and Copeptin in Advanced Heart Failure in Patients with Preserved and Mildly Reduced Ejection Fraction and Type 2 Diabetes Mellitus.Medicina (Kaunas, Lithuania) · 2024Article
- In vitro and in vivo effects of Galectin-3 inhibitor TD139 on inflammation and ERK/JNK/p38 pathway in gestational diabetes mellitus.The Kaohsiung journal of medical sciences · 2024Article
- Metabolic profiling of galectin-1 and galectin-3: a cross-sectional, multi-omics, association study.International journal of obesity (2005) · 2024Article
- Galectin 3 rs4644 gene polymorphism is associated with metabolic traits in Serbian adolescent population.Journal of medical biochemistry · 2024Article
- Review
- Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study.Journal of the American Heart Association · 2024Article
- Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet.Current research in pharmacology and drug discovery · 2024Article
- Association between serum Galectin-3 and periodontitis in patients with type 2 diabetes mellitus.Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2023Article
- Galectin-3 Mediates Vascular Dysfunction in Obesity by Regulating NADPH Oxidase 1.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galectin-3 is an important modulator of several biological functions. It has been implicated in numerous disease conditions, particularly in the long-term complications of diabetes because of its ability to bind the advanced glycation/lipoxidation end products that accumulate in target organs and exert their toxic effects by triggering proinflammatory and prooxidant pathways. Recent evidence suggests that galectin-3 may also participate in the development of obesity and type 2 diabetes. It has been shown that galectin-3 levels are higher in obese and diabetic individuals and parallel deterioration of glucose homeostasis. Two studies in galectin-3 knockout mice fed a high-fat diet (HFD) have shown increased adiposity and adipose tissue and systemic inflammation associated with altered glucose homeostasis, suggesting that galectin-3 negatively modulates the responsiveness of innate and adaptive immunity to overnutrition. However, these studies have also shown that impaired glucose homeostasis occurs in galectin-3 knockout animals independently of obesity. Moreover, another study reported decreased weight and fat mass in HFD-fed galectin-3 knockout mice. In vitro, galectin-3 was found to stimulate differentiation of preadipocytes into mature adipocytes. Altogether, these data indicate that galectin-3 deserves further attention in order to clarify its role as a potential player and therapeutic target in obesity and type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.